Tumorigenesis is a complex process, which requires alterations in several tumor suppressor or oncogenes. Here, we use a Drosophila tumor model to identify genes, which are specifically required for tumor growth. We found that reduction of phosphoinositide 3-kinase (PI3K) activity resulted in very small tumors while only slightly affecting growth of wild-type tissue. The observed inhibition on tumor growth occurred at the level of cell-cycle progression. We conclude that tumor cells become dependent on PI3K function and that reduction of PI3K activity synthetically interferes with tumor growth. The results presented here broaden our insights into the intricate mechanisms underling tumorigenesis and illustrate the power of Drosophila genetics in revealing weak points of tumor progression.
Introduction
Ideal cancer therapies target tumor cells while not harming non-cancer cells. However, many of today's cancer therapies target general processes that are also required in non-cancer cells and thus can cause significant damage and side effects in normal tissues. One strategy to develop more specific therapies is to search for potential drug targets that are required for the survival and/or growth of cancer cells but not normal cells. Inhibition of such targets would produce so-called synthetic phenotypes as the effects are only seen in combination with the mutations present in cancer cells (Kaelin, 2005) . Here, we employed a genetic tumor model in Drosophila imaginal discs to systematically screen for synthetic phenotypes in vivo.
Recently, Drosophila tumor models have been established that are based on defined and reproducible genetic manipulation of tumor suppressor and oncogenes (Brumby and Richardson, 2003; Pagliarini and Xu, 2003) . These models consist of cells that have defective cell polarity and activated Ras signaling. Loss of polarity is induced by loss of Scribble (Scrib), which is required for apico-basal polarity together with Discs large (Dlg) and Lethal giant larvae (Lgl) (Stewart et al., 1972; . Ras signaling was augmented through overexpression of a constitutively active version of Ras, Ras V12 (Brumby and Richardson, 2003; Pagliarini and Xu, 2003) . Cells that are mutant for scrib and simultaneously express Ras V12 proliferate in an uncontrolled manner, pile on top of each other (neoplastic growth) and gain the ability to migrate into surrounding tissues (Brumby and Richardson, 2003; Pagliarini and Xu, 2003) . Ras
V12
, scrib tumors can therefore be used to identify and study genes that are required for neoplastic tumor growth in Drosophila.
Here, we used a modified version of the Ras
, scrib tumor model to identify genes required for neoplastic tumor growth. We found that reduction of phosphoinositide 3-kinase (PI3K) signaling blocks cell-cycle progression in these tumors, but has only weak effects in wild-type cells. Reduction of PI3K signaling, therefore, synthetically interferes with tumor growth in a Drosophila tumor model.
Results

Ras
V12 , Dlg
RNAi tumors critically depend on PI3K signaling To identify genes required for growth of Ras V12 , scrib tumors, we modified the original assay (Brumby and Richardson, 2003; Pagliarini and Xu, 2003) , such that it allows to screen for changes in the tumor phenotype by simply crossing a tester stock to a stock containing a UAS transgene. The tester stock overexpresses Ras V12 as well as a dsRNAi construct targeting the polarity gene discs large (hereafter referred to as Ras V12 , Dlg RNAi ). This results in a neoplastic phenotype, which is similar to that of Ras V12 , scrib clones ( Figure 1a) . Our assay has the advantage that all components required to cause the neoplastic phenotype are driven by UAS promoters; and therefore, the neoplastic phenotype can simply be induced by driving their expression via Gal4. Specifically, we used an FLP-out Gal4 transgene that stably expresses Gal4 on FLP-induced recombination together with an eyeless promoter-driven FLP transgene (ey-FLP) that drives FLP expression in developing eye discs from early stages onwards (Newsome et al., 2000) .
We screened a set of 200 UAS-RNAi lines, which was enriched for genes implicated in epithelial-to-mesenchymal transition and neoplastic growth, for possible suppression of Ras V12 , Dlg
RNAi tumor growth. In this screen, we identified PI3K
RNAi and Akt RNAi as strong suppressors of the growth caused by Ras V12 , Dlg
RNAi . PI3K and Akt are both components of the PI3K pathway (Leevers et al., 1996; Verdu et al., 1999; Weinkove et al., 1999; Scanga et al., 2000) . Knockdown of either gene in an Ras V12 ,
Dlg
RNAi background caused a complete suppression of the neoplastic growth and even caused a near-complete absence of mutant eye cells (Figures 1a-c and m) . Only small structures, which contained few cells, remained.
To exclude the possibility that these growth-suppressing effects were due to off-target effects of the RNAi lines or due to titration of Gal4 by multiple UAS constructs, we tested whether genomic mutations in the PI3K gene could also suppress the growth of Ras V12 ,
RNAi tumors. We used the MARCM system (Lee and Luo, 2001) RNAi(101475) , (e) none, (f) UAS-PI3K RNAi(38985) , (g) UAS-Akt RNAi(2902) and (h) UAS-Pten RNAi(101475) . The discs shown in (i-l) carry ey-FLP MARCM clones (Lee and Luo, 2001) . Clones are positively marked by expression of GFP (green) and discs are stained for E-cadherin to visualize the disc outlines (red RNAi tumors to changes in PI3K signaling could be that tissue overgrowth requires a higher metabolic rate than normal. The PI3K pathway regulates metabolism (Britton et al., 2002) and may therefore be more rate limiting for the growth of tumor cells than wild-type cells. To test whether this is the case, we manipulated other tumor suppressor pathways to generate tissue overgrowths and tested whether these overgrowths were also sensitive to manipulation of the PI3K pathway. Either downregulation of the Hippo tumor suppressor pathway by overexpression of the Yorki (Yki) transcriptional activator or misregulation of the JAK-STAT pathway by overexpression of the Unpaired (Upd) ligand caused overgrown imaginal disc tissues (Bach et al., 2003; Huang et al., 2005 (Wu et al., 2010) . In all these set-ups, knockdown of PI3K signaling reduced the size of the discs (Figures 2g-l) . However, the growthsuppressing effect was much weaker than that observed for the Ras V12 , Dlg RNAi tumors and seemed to be additive rather than synthetic (compare Figures 1a, b , e, f and 2b-f, h-l). Thus, the sensitivity to changes in the levels of PI3K signaling is not a general feature of overgrowing tissues, but is specific to Ras V12 , Dlg
RNAi tumors.
Joint misregulation of Dlg and Ras elicits PI3K dependency
In the above experiment, we found that Ras RNAi (41134) , (f) UAS-Upd, UAS-Ras V12 , (g) UAS-PI3K RNAi(38985) , (h) UAS-Yki, UAS-PI3K RNAi(38985) , (i) UAS-Upd, UAS-PI3K (Figures 3a-c) . In both cases, coexpression of PI3K RNAi suppressed tumor growth but the suppression was less strong than that observed in the Ras V12 , Dlg RNAi situation (Figures 3d-f) . Thus, PI3K dependency appears to be a consequence of the simultaneous loss of cell polarity and gain of Ras activity. (Figures 4c and g ), mimicking the situation of the eye tumors. Notably, PI3K
PI3K depletion blocks tumor cell-cycle progression
RNAi expression had only mild growth-suppressing effects in otherwise wild-type compartments (Figures 4d and g ). These observations in the wing imaginal discs are consistent with our findings in eye discs and provide further support for the notion that Ras V12 , Dlg
RNAi cells are more sensitive to changes in PI3K activity than wild-type cells.
We assayed the different genotypes for changes in cell proliferation by using the M-phase marker phosphohistone H3 (PH3). We found that Ras V12 , Dlg
RNAiexpressing wing discs exhibit high levels of cell proliferation (Figures 4a, b, h and i RNAi -expressing cells to reenter the cell cycle, we coexpressed the transgenes together with the G1 to S-phase regulator Cyclin E (CycE) (Knoblich et al., 1994; Richardson et al., 1995) and the G2 to M-phase regulator String (Stg) (Edgar and O'Farrell, 1990 RNAi cells are competent, in principle, to go through the cell cycle but are prevented from doing so as a consequence of their altered signaling state.
When we looked for apoptosis by monitoring caspase 3 cleavage (Supplementary Figures S2A-D Figures S2B-D) . This indicates that the size reduction caused by PI3K
RNAi is not due to extra apoptosis.
JAK-STAT signaling is insensitive to PI3K depletion Studies with Ras
V12
, scrib tumors have shown that polarity defects caused by loss of scrib result in ectopic activation of the JNK and JAK-STAT pathways and that ectopic JAK-STAT activity cooperates with Ras V12 to induce tumor growth (Wu et al., 2010) . Since the PI3K pathway is required for Ras V12 , Dlg
RNAi tumor growth, we investigated whether PI3K activates JAK-STAT signaling as a consequence of polarity defects. JAK-STAT signaling activity was monitored with a STAT-GFP reporter (Bach et al., 2007) in wild-type discs and in discs that expressed Ras Figure 3 The combination of Ras V12 and Dlg RNAi elicits PI3K dependency. Third instar eye imaginal discs, which carry a FLPout Gal4 transgene that stably expresses Gal4 after FLP-induced recombination. FLP is expressed in eye discs with an eyeless promoter-driven FLP transgene. The discs carry a UAS-GFP transgene to mark Gal4-expressing cells (green). Discs coexpress the following transgenes: (a) UAS-Dlg RNAi(41134) , (b) UAS-Ras V12 , (c) UAS-Dlg RNAi(41134) , UAS-Ras V12 , (d) UAS-Dlg RNAi(41134) , UAS-PI3K RNAi(38985) , (e) UAS-Ras V12 , UAS-PI3K RNAi(38985) and (f) UASRas V12 , UAS-Dlg RNAi(41134) , UAS-PI3K RNAi(38985) . (c) Is a composite of several individual images needed to display the complete tumor size.
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Overexpression of Ras
V12
, Dlg RNAi in the posterior compartment induced ectopic STAT-GFP expression in the wing pouch (Figure 5b) , which is consistent with a previously observed upregulation of the JAK-STAT pathway in scrib mutants (Wu et al., 2010) . When we depleted PI3K in Ras , UAS-PI3K RNAi(38985) , (d) UAS-PI3K RNAi(38985) , (e) UAS-Ras V12 , UAS-Dlg RNAi(41134) , UAS-PI3K RNAi(38985) , UAS-Cyclin E, UAS-String. Discs were stained for Fasciclin 3 to visualize disc outlines (blue) and for PH3 to mark cells in M-phase ((a-f) in red and (a 00 -e 00 ) and (f 0 ) in gray). 
PI3K signaling is low in Ras
V12
, Dlg RNAi tumors From mammalian systems, it is known that Ras binds to PI3K and that oncogenic transformation in response to Ras depends on PI3K activity (Rodriguez-Viciana et al., 1994 , 1997 Gupta et al., 2007) . In Drosophila, it was shown that PI3K is not required for physiological Ras signaling (Halfar et al., 2001; Prober and Edgar, 2002) . However, PI3K activity, monitored by a PIP 3 reporter, was increased in cells expressing oncogenic Ras V12 (Prober and Edgar, 2002) , indicating that abnormally high levels of Ras activity can lead to PI3K activation in Drosophila. We studied PI3K signaling levels in the Ras V12 , Dlg
RNAi tumor assay to test for a possible correlation between PI3K signaling levels and PI3K sensitivity. To measure PI3K signaling levels, we monitored by western blotting pAkt levels in eye imaginal discs, which expressed different transgene combinations. To show that the antibody detects PI3K pathway activity, we monitored the increase of pAkt levels upon RNAi-targeting PTEN (Figure 5d, lane 1) . Consistent with the results of Prober and Edgar (2002), we also found high levels of pAkt in discs, which expressed Ras V12 (Figure 5d , lane 5). Discs that expressed Dlg RNAi had lower levels of pAkt (Figure 5d , lane 6). When Ras V12 and Dlg RNAi were coexpressed we made the interesting observation that these tumors had low levels of pAkt (Figure 5d, lane 3) (Figure 5d , lane 4). As discussed below the finding that PI3K signaling levels are low in Ras V12 -expressing tumors lacking Dlg provides a potential explanation for the sensitivity of such tumor to reduction of PI3K signaling components.
Discussion
In this study, we employed a genetic approach to identify genes required for the neoplastic growth phenotype of Ras , UAS-PI3K RNAi(38985) . (d) Western blot to detect pAkt and a-Tubulin levels from third instar eye imaginal discs. The pAkt antibody detects a double band, which is also described in the Cell Signaling Technology product information.
Loss of PI3K blocks Drosophila tumor growth M Willecke et al of the PI3K pathway and that changes in PI3K activity block cell-cycle progression.
In agreement with previous reports, we find that Ras V12 induces the PI3K pathway in Drosophila (Prober and Edgar, 2002 (Figure 2 ). The pAkt western blot in Figure 5 shows, however, that these tumors have high levels of PI3K signaling. Expression of PI3K RNAi in this background might not cause PI3K activity to drop below a threshold for cellcycle progression.
Compounds that block PI3K pathway activity are known to be potent inhibitors of mammalian tumor growth and inhibitors that target PI3K, and other members of the pathway are currently being tested in clinical trials (Hennessy et al., 2005; Cleary and Shapiro, 2010; Courtney et al., 2010) . Preclinical and clinical trials focus mainly on tumors that carry mutations in PI3K pathway components or that display abnormal levels of the biomarkers pAKT and PS6k1 (Hennessy et al., 2005; Cleary and Shapiro, 2010; Courtney et al., 2010) . Our results are, however, an example for a case where tumors with no genetic alterations in PI3K signaling components are also highly susceptible to reduction of PI3K levels. Understanding the molecular networks that create such PI3K dependency is a central topic in cancer research as it is highly relevant to identify PI3K-dependent tumors to predict the potential effectiveness of PI3K inhibitors. Genetic studies in Drosophila may therefore complement mammalian studies to more precisely determine which tumor-initiating pathways create PI3K sensitivity.
In conclusion, we have uncovered a synthetic interaction between the Drosophila PI3K signaling and Ras
V12
, Dlg
RNAi tumor-initiating pathways. The results presented here broaden our insights into the complex mechanisms underlying tumorigenesis and illustrate the power of Drosophila genetics in revealing the vulnerabilities of tumors. Identification of additional synthetic interactions through genetic screening in Drosophila may serve as a valuable resource for identifying potential drug targets in cancer therapy. 1C1 is a PI3K mutation that was obtained in an ethane methyl sulfonate (EMS) screen in the laboratory of Ernst Hafen by Hugo Stocker. For expression of different transgene combinations in the posterior compartment the transgenes indicated in the figure were crossed to a stock of the genotype: enGal4, UAS-CD8-GFP, Gal80 ts . The progeny was kept on 18 1C for 96 h then transferred to 29 1C and kept for 48 h. Other stocks used were UAS-Akt RNAi(2902) , UAS-PI3K RNAi(38985) , UAS-Pten RNAi(101475) UAS-InR RNAi(992) , UAS-S6k RNAi(18126) UASRheb RNAi(1081RÀ2) UAS-Tor RNAi(5092RÀ2) UAS-Yki, UAS-Upd and STAT-GFP (BL#26198) .
Materials and methods
Fly stocks and genetics
Western blot
Eye discs were dissected in Ringer's solution and then lysed in sodium dodecyl sulfate (SDS) sample buffer. Western blots were performed according to standard protocols. Antibodies used were a-pAkt (Cell Signaling, Beverly, MA, USA, #40545, 1:1000) and a-a-Tubulin (Sigma, St Louis, MO, USA, 1:10 000). experiments; and H Stocker, the Bloomington Stock Center, the National Institute of Genetics (NIG) and the Vienna Drosophila RNAi Center (VDRC) for fly strains. This work was supported by an FEBS Long-term Fellowship to MW, the Swiss National Science Foundation and the Kanton of Zurich.
